Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)

#972

Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.

Aim(s): To evaluate the efficacy of long-acting SSA in NET pts according to Ki-67 score.

Materials and methods: An observational Italian multicentric study was designed to collect data on NET pts under treatment with SSA. The observational data were collected through an e-CRF and stored in a centralized computer database. Both retrospective data of pts in treatment with SSA from 2005 and prospective data of pts treated with SSA from March 2012 to November 2012 were included. Study population included 280 pts who have had a histological diagnosis of NET (77 thoracic, 80 pancreatic, 83 gastro-intestinal, 40 unknown primary tumors). Among these, 134 have been treated with octreotide LAR or lanreotide autogel. These form the basis of the statistical analysis.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Faggiano A

Authors: Faggiano A, Carratù A, Tafuto S, Lastoria S, Von Arx C,

Keywords: NET, SSA, G1, G2, WHO classification,